PDCD1 and non-small cell lung carcinoma: Nevertheless, recent clinical trials involving anti-PD-1 therapy have revealed that only 15–25% of patients with NSCLC responded to immune checkpoint blockade therapy alone, regardless of their PD-L1 expression [3–5].